There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > KIR2DL3


KIR2DL3 Molecule Information

Name:Killer cell immunoglobulin-like receptor 2DL3
Target Synonym:NKAT2b;p58 natural killer cell receptor clone CL-6;Killer inhibitory receptor cl 2-3;NKAT2a;MHC class I NK cell receptor;NKAT-2;KIRCL23;Natural killer-associated transcript 2;p58 NK receptor CL-6;KIR2DL3;p58.2 MHC class-I-specific NK receptor;CD158B2 ;KIR
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase ?

KIR2DL3 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
KI3-H5257 Human Human KIR2DL3 / CD158b2 Protein, Fc Tag
KI3-H5226 Human Human KIR2DL3 / CD158b2 Protein, His Tag

KIR2DL3 Molecule Synonym Name


KIR2DL3 Molecule Background

Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is also known as CD158 antigen-like family member B2, KIR-023GB, Killer inhibitory receptor cl 2-3, MHC class I NK cell receptor, NKAT2a, NKAT2b, Natural killer-associated transcript 2, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158b2 and KIR2DL3, which is a single-pass type I membrane protein and belongs to the immunoglobulin superfamily.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). KIR2DL3 can inhibit the activity of NK cells thus preventing cell lysis.

KIR2DL3 References

KIR2DL3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lirilumab BMS-986015; IPH-21; IPH-2101; IPH-2102; NN-1975 Phase Ⅱ Novo Nordisk, Bristol-Myers Squibb, Ono Pharmaceutical, Innate Myelodysplastic syndrome (MDS), Chronic lymphocytic leukemia (CLL), hematological malignancies, Solid tumours, Multiple myeloma (MM), Acute myeloid Leukemia (AML) Details

This web search service is supported by Google Inc.